[go: up one dir, main page]

ATE219366T1 - Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b - Google Patents

Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b

Info

Publication number
ATE219366T1
ATE219366T1 AT92906520T AT92906520T ATE219366T1 AT E219366 T1 ATE219366 T1 AT E219366T1 AT 92906520 T AT92906520 T AT 92906520T AT 92906520 T AT92906520 T AT 92906520T AT E219366 T1 ATE219366 T1 AT E219366T1
Authority
AT
Austria
Prior art keywords
thiacytidine
deoxy
fluoro
treat hepatitis
hepatitis
Prior art date
Application number
AT92906520T
Other languages
English (en)
Inventor
Dennis C Liotta
Raymond F Schinazi
Woo-Baeg Choi
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919104741A external-priority patent/GB9104741D0/en
Priority claimed from GB919109505A external-priority patent/GB9109505D0/en
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE219366T1 publication Critical patent/ATE219366T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT92906520T 1991-03-06 1992-03-05 Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b ATE219366T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919104741A GB9104741D0 (en) 1991-03-06 1991-03-06 Therapeutic nucleosides
GB919109505A GB9109505D0 (en) 1991-05-02 1991-05-02 Therapeutic nucleosides
PCT/GB1992/000388 WO1992015308A1 (en) 1991-03-06 1992-03-05 Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b

Publications (1)

Publication Number Publication Date
ATE219366T1 true ATE219366T1 (de) 2002-07-15

Family

ID=26298535

Family Applications (2)

Application Number Title Priority Date Filing Date
AT92906520T ATE219366T1 (de) 1991-03-06 1992-03-05 Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
AT01202860T ATE361293T1 (de) 1991-03-06 1992-03-05 Salze und amide von (-) cis 5-fluoro-2'-deoxy-3'- thiacytidine geeignet für die behandlung von hepatitis b

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01202860T ATE361293T1 (de) 1991-03-06 1992-03-05 Salze und amide von (-) cis 5-fluoro-2'-deoxy-3'- thiacytidine geeignet für die behandlung von hepatitis b

Country Status (21)

Country Link
EP (3) EP1808434A3 (de)
JP (5) JP3479068B2 (de)
KR (1) KR100270806B1 (de)
AT (2) ATE219366T1 (de)
AU (1) AU662130B2 (de)
CA (1) CA2105486C (de)
CZ (1) CZ282747B6 (de)
DE (2) DE69232649T2 (de)
DK (2) DK1142891T3 (de)
ES (2) ES2286072T3 (de)
HU (1) HUT64844A (de)
IE (1) IE920701A1 (de)
IL (1) IL101144A (de)
MX (1) MX9203213A (de)
NZ (1) NZ264621A (de)
PT (1) PT100198B (de)
RU (1) RU2116789C1 (de)
SK (1) SK279542B6 (de)
TW (1) TW201268B (de)
UA (1) UA54364C2 (de)
WO (1) WO1992015308A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2152269C (en) * 1989-02-08 1999-09-21 Bernard Belleau (Deceased) Process for preparing substituted 1,3-oxathiolanes with antiviral properties
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
WO1995007086A1 (en) * 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
AU722214B2 (en) 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
EA005097B1 (ru) * 1997-03-19 2004-10-28 Эмори Юниверсити Синтез 1,3-оксаселеноланнуклеозидов, обладающих активностью против вируса иммунодефицита человека и против вируса гепатита-b
DE69929060T2 (de) 1998-08-10 2006-08-31 Idenix (Cayman) Ltd. Beta-l-2'-deoxynukleoside für die behandlung von hepatitis b virus
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
RU2244712C2 (ru) 1998-08-12 2005-01-20 Гайлид Сайенсиз, Инк. Способ получения 1,3-оксатиоланового нуклеозида, способ получения производного 1,3-оксатиоланил-5-она
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
RU2237479C2 (ru) * 1998-11-05 2004-10-10 Сантр Насьональ Де Ля Решерш Сьентифик Нуклеозиды, обладающие активностью против вируса гепатита в
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
YU92202A (sh) 2000-05-26 2006-01-16 Idenix (Cayman) Limited Metode i smeše za lečenje flavi virusa i pesti virusa
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US7589077B2 (en) 2001-05-18 2009-09-15 Rakesh Kumar Antiviral nucleosides
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
AU2003278816A1 (en) 2002-09-13 2004-04-30 Idenix (Cayman) Limited ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
PT1576138T (pt) 2002-11-15 2017-05-03 Idenix Pharmaceuticals Llc 2'-metil-nucleósidos em combinação com interferão e mutação de flaviviridae
RU2005121904A (ru) 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) Способ получения 2`-разветвленных нуклеозидов
US9320738B2 (en) 2008-06-30 2016-04-26 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
WO2013004658A1 (en) * 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK224286A (da) * 1985-05-15 1986-11-16 Wellcome Found 2',3'-dideoxy-nucleosider
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
CA2055433A1 (en) 1989-05-15 1990-11-16 Jay H. Hoofnagle Method of treatment of hepatitis
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides

Also Published As

Publication number Publication date
EP1808434A2 (de) 2007-07-18
AU662130B2 (en) 1995-08-24
IE920701A1 (en) 1992-09-09
NZ264621A (en) 1997-09-22
JP2010013466A (ja) 2010-01-21
EP1142891B1 (de) 2007-05-02
DK1142891T3 (da) 2007-08-27
JPH06505725A (ja) 1994-06-30
JP2007246536A (ja) 2007-09-27
HU9302493D0 (en) 1993-11-29
ES2179040T3 (es) 2003-01-16
CA2105486A1 (en) 1992-09-07
DE69233693D1 (de) 2007-06-14
JP2011102308A (ja) 2011-05-26
ATE361293T1 (de) 2007-05-15
IL101144A (en) 1996-09-12
JP3987335B2 (ja) 2007-10-10
SK95093A3 (en) 1994-04-06
TW201268B (de) 1993-03-01
JP4399478B2 (ja) 2010-01-13
EP1142891A1 (de) 2001-10-10
DK0574487T3 (da) 2002-10-14
DE69232649T2 (de) 2002-11-28
WO1992015308A1 (en) 1992-09-17
PT100198A (pt) 1993-05-31
ES2286072T3 (es) 2007-12-01
IE20040402A1 (en) 2007-10-17
JP4891435B2 (ja) 2012-03-07
CZ282747B6 (cs) 1997-09-17
KR100270806B1 (ko) 2000-11-01
JP2002220388A (ja) 2002-08-09
EP0574487B1 (de) 2002-06-19
MX9203213A (es) 1992-07-01
DE69233693T2 (de) 2008-01-24
CZ183593A3 (en) 1994-04-13
HUT64844A (en) 1994-03-28
EP1808434A3 (de) 2008-04-02
RU2116789C1 (ru) 1998-08-10
JP3479068B2 (ja) 2003-12-15
CA2105486C (en) 2003-10-28
UA54364C2 (uk) 2003-03-17
PT100198B (pt) 2000-03-31
AU1367692A (en) 1992-10-06
DE69232649D1 (de) 2002-07-25
EP0574487A1 (de) 1993-12-22
IL101144A0 (en) 1992-11-15
SK279542B6 (sk) 1998-12-02

Similar Documents

Publication Publication Date Title
ATE219366T1 (de) Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
ITMI931522A0 (it) Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv)
ATE329598T1 (de) 1,3-oxathiolane zur behandlung von hepatitis
DK224286D0 (da) 2',3'-dideoxy-nucleosider
YU74992A (sh) Postupak za pravljenje (-)4-amino-5-fluoro-1-(2-hidroksimetil-1,3-oksatiolan-5-il)-(1h)-pirimidin-2-ona
RU93043875A (ru) 1-(2-гидроксиметил)-1,3-оксатиолан-5-ил)-5-фторцитозин и способ лечения
RU94013464A (ru) Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции
GEP19991834B (en) Crystalline Oxathiolane Derivatives
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
MD950086A (ro) Utilizare a analogilor nucleozidici ai 1,3-oxatiolanei in tratamentul hepatitei B Use of 1,3-oxathiolan nucleoside analogues in the treatment of hepatitis B
DK602988D0 (da) Nukleosidderivater med antiviral virkning og laegemiddelpraeparat indeholdende saadanne forbindelser
DE3773892D1 (de) Medizinische verwendung von nukleosiden.
MY127808A (en) Use of dideoxy nucleoside analogues in the treatment of viral infections
NO931246D0 (no) Sammensetninger for behandling av infeksjon og sykdom foraarsaket av hepatites b virus (hbv)
MY137298A (en) Therapeutic nucleosides
DE69019404D1 (de) Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen.
PT87004A (pt) Process for the preparation of compositions for the treatment of viral infections and composites 3'-azide-2',3'-didesoxy-in osine and 3'-fluoro-2',3'-didesoxyguanosine
RU93058325A (ru) Применение производных 1,3-оксатиолана для получения лекарственных препаратов для лечения или профилактики вирусной инфекции гепатита в, применение производных 1,3 - оксатиолана для лечения инфекций гепатита в, способ лечения гепатита в
MY113560A (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
YU221289A (en) Antivirus compounds
ATE100318T1 (de) Verwendung von chinolyl- und isochinolyloxazol-2- onen zur herstellung eines arzneimittels zur verhinderung der ansteckungsfaehigkeit von mit glykoproteinen umhuellten viren.
GR920100326A (el) Ενώσεις και μέ?οδοι αναστολής του HIV και των σχετικών ιών.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification